Regeneron a 'national strategic asset' for quick response to COVID-19 outbreak: analyst

regeneron
Despite Regeneron's inside track on a COVID-19 treatment, the virus could spell trouble for blockbuster Eylea's sales. (Regeneron)

Drugmakers of all shapes and sizes are chasing after therapeutics and vaccines to fight the novel coronavirus. But among the pack, one company's track record might give it the jump on a treatment—and at least one analyst is not afraid to heap praise on its efforts. 

Regeneron's "innovative horsepower and initiative" in its response to COVID-19, including a push to repurpose arthritis med Kevzara and quickly identify new antibodies to target the virus, has put the drugmaker in the lead to develop a treatment, Evercore ISI analyst Josh Schimmer said in a note to investors Friday.

After a luncheon with CEO Len Schleifer, Schimmer touted Regeneron's response not only to COVID-19 but also Ebola as a "national strategic asset" for the U.S. given the drugmaker's quick mobilization in outbreaks.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

"Our most important takeaway is that the COVID pandemic is a lesson of how lucky the country is to have (Regeneron)––it is poised to perhaps have the biggest impact on this outbreak," Schimmer wrote. 

RELATED: Could arthritis med Kevzara hold promise against the novel coronavirus? Sanofi, Regeneron aim to find out

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.